Quantitative determination and pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rat brain by high performance liquid chromatography-tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 66, Issue , 2012, Pages 232-239

  Hou, Jinfeng ^a   Qu, Feng ^a   Wu, Caisheng ^a   Ren, Qiang ^a   Zhang, Jinlan ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Anti Parkinson's disease; FLZ; High performance liquid chromatography tandem mass spectrometry; Pharmacokinetics; Rat brain

Indexed keywords

ACETIC ACID; ACETIC ACID ETHYL ESTER; ACETONITRILE; ANTIPARKINSON AGENT; BREAST CANCER RESISTANCE PROTEIN; CARBAMAZEPINE; GLYCOPROTEIN P; HEXANE; N [2 (4 HYDROXY PHENYL)ETHYL] 2 (2,5 DIMETHOXY PHENYL) 3 (3 METHOXY 4 HYDROXYPHENYL)ACRYLAMIDE; UNCLASSIFIED DRUG; ZOSUQUIDAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BRAIN; BRAIN HOMOGENATE; BRAIN TISSUE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG PENETRATION; DRUG STABILITY; DRUG STRUCTURE; ELECTROSPRAY; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN TRANSPORT; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION STUDY;

ACRYLAMIDES; ANIMALS; ANTIPARKINSON AGENTS; BIOLOGICAL TRANSPORT; BRAIN; CAFFEIC ACIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIBENZOCYCLOHEPTENES; LIMIT OF DETECTION; MALE; P-GLYCOPROTEIN; QUINOLINES; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 84861225154     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.03.001     Document Type: Article

References (28)

1. Xie P., Jiao X.Z., Liang X.T., Feng W.H., Wei H.L., Liu G.T. Synthesis and antioxiactivity of squamosamide cycnc analogs. Acta Acad. Med. Sin. 2004, 26:372-378.
2. Zhang D., Zhang J.J., Liu G.T. The novel squamosamide derivative (compound FLZ) attenuated 1-methyl, 4-phenyl-pyridinium ion (MPP+)-induced apoptosis and alternations of related signal transduction in SH-SY5Y cells. Neuropharmacology 2007, 52:423-429.
3. Feng W., Wei H., Liu G.T. Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism. Mol. Neurobiol. 2005, 31:295-300.
4. Zhang D., Zhang J.J., Liu G.T. The novel squamosamide derivative FLZ protects against 6-hydroxydopamine-induced apoptosis through inhibition of related signal transduction in SH-SY5Y cells. Eur. J. Pharmacol. 2007, 561:1-6.
5. Kong X.C., Zhang D., Qian C., Liu G.T., Bao X.Q. FLZ, a novel HSP27 and HSP70 inducer, protects SH-SY5Y cells from apoptosis caused by MPP(+). Brain Res. 2011, 1383:99-107.
6. Bao X.Q., Kong X.C., Qian C., Zhang D. FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models. Neuroscience 2012, 202:396-404.
7. Zhang D., Hu X., Wei S.J., Liu J., Gao H., Qian L., Wilson B., Liu G., Hong J.S. Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity. J. Neuroinflamm. 2008, 5:21.
8. Li N., Liu G.T. The novel squamosamide derivative FLZ enhances BDNF/TrkB/CREB signaling and inhibits neuronal apoptosis in APP/PS1 mice. Acta Pharmacol. Sin. 2010, 31:265-272.
9. Hou Y., Yu Y.B., Liu G., Luo Y. A natural squamosamide derivative FLZ reduces amyloid-beta production by increasing non-amyloidogenic AbetaPP processing. J. Alzheimers Dis. 2009, 18:153-165.
10. Graff C.L., Pollack G.M. Drug transport at the blood-brain barrier and the choroid plexus. Curr. Drug Metab. 2004, 5:95-108.
11. Demeule M., Regina A., Jodoin J., Laplante A., Dagenais C., Berthelet F., Moghrabi A., Beliveau R. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul. Pharmacol. 2002, 38:339-348.
12. Enokizono J., Kusuhara H., Ose A., Schinkel A.H., Sugiyama Y. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab. Dispos. 2008, 36:995-1002.
13. Enokizono J., Kusuhara H., Sugiyama Y. Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol. Pharmacol. 2007, 72:967-975.
14. Potschka H., Fedrowitz M., Loscher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci. Lett. 2002, 327:173-176.
15. Schinkel A.H. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug. Deliv. Rev. 1999, 36:179-194.
16. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 2004, 104:29-45.
17. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005, 2:3-14.
18. Li L.B., Zhang J.L., Wang Y.X., Wei H.L., Liu G.T. Establishment of a HPLC method for preclinical pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rats. Biomed. Chromatogr. 2008, 22:867-872.
19. Paxinos G., Watson C. The Mouse Brain in Stereotaxic Coordinates 2005, People's Medical Publishing House, Beijing. third edition.
20. Brown E.A., Griffiths R., Harvey C.A., Owen D.A. Pharmacological studies with SK&F 93944 (temelastine), a novel histamine H1-receptor antagonist with negligible ability to penetrate the central nervous system. Br. J. Pharmacol. 1986, 87:569-578.
21. Raje S., Cao J., Newman A.H., Gao H., Eddington N.D. Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. J. Pharmacol. Exp. Ther. 2003, 307:801-808.
22. Covy J.P., Giasson B.I. Alpha-synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of parkinson disease. Neurotoxicology 2011.
23. Panneton W.M., Kumar V.B., Gan Q., Burke W.J., Galvin J.E. The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One 2010, 5:e15251.
24. Dantzig A.H., Shepard R.L., Law K.L., Tabas L., Pratt S., Gillespie J.S., Binkley S.N., Kuhfeld M.T., Starling J.J., Wrighton S.A. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J. Pharmacol. Exp. Ther. 1999, 290:854-862.
25. Shepard R.L., Cao J., Starling J.J., Dantzig A.H. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int. J. Cancer 2003, 103:121-125.
26. Allen J.D., van Loevezijn A., Lakhai J.M., van der Valk M., van Tellingen O., Reid G., Schellens J.H., Koomen G.J., Schinkel A.H. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer. Ther. 2002, 1:417-425.
27. Chen Y., Agarwal S., Shaik N.M., Chen C., Yang Z., Elmquist W.F. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J. Pharmacol. Exp. Ther. 2009, 330:956-963.
28. de Vries N.A., Zhao J., Kroon E., Buckle T., Beijnen J.H., van Tellingen O. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin. Cancer Res. 2007, 13:6440-6449.